These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29633520)

  • 1. How far are we from viral hepatitis elimination service coverage targets?
    Hutin YJ; Bulterys M; Hirnschall GO
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25050. PubMed ID: 29633520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    Qureshi H; Mahmood H; Sabry A; Hermez J
    J Infect Dis; 2023 Sep; 228(Suppl 3):S204-S210. PubMed ID: 37703344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global reporting of progress towards elimination of hepatitis B and hepatitis C.
    Cui F; Blach S; Manzengo Mingiedi C; Gonzalez MA; Sabry Alaama A; Mozalevskis A; Séguy N; Rewari BB; Chan PL; Le LV; Doherty M; Luhmann N; Easterbrook P; Dirac M; de Martel C; Nayagam S; Hallett TB; Vickerman P; Razavi H; Lesi O; Low-Beer D
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):332-342. PubMed ID: 36764320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for acute viral hepatitis - United States, 2007.
    Daniels D; Grytdal S; Wasley A;
    MMWR Surveill Summ; 2009 May; 58(3):1-27. PubMed ID: 19478727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets.
    Spearman CW; Afihene M; Ally R; Apica B; Awuku Y; Cunha L; Dusheiko G; Gogela N; Kassianides C; Kew M; Lam P; Lesi O; Lohouès-Kouacou MJ; Mbaye PS; Musabeyezu E; Musau B; Ojo O; Rwegasha J; Scholz B; Shewaye AB; Tzeuton C; Sonderup MW;
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):900-909. PubMed ID: 29132759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress towards elimination of viral hepatitis by 2030 in the WHO Eastern Mediterranean Region, 2019.
    Alaama AS; Khattabi H; Mugisa B; Atta H; Hermez J; Hutin YJ
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):862-870. PubMed ID: 35817075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
    Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action.
    Al Awaidy ST; Ezzikouri S
    J Infect Public Health; 2020 Feb; 13(2):221-227. PubMed ID: 31445879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress on global hepatitis elimination targets.
    Waheed Y
    World J Gastroenterol; 2021 Dec; 27(47):8199-8200. PubMed ID: 35068864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting.
    Le LV; Blach S; Rewari B; Chan P; Fuqiang C; Ishikawa N; Sharma M; Mangadan-Konath N; Razavi H; Low-Beer D; Razavi-Shearer D
    Liver Int; 2022 Aug; 42(9):1930-1934. PubMed ID: 34894047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis elimination by 2030: Progress and challenges.
    Waheed Y; Siddiq M; Jamil Z; Najmi MH
    World J Gastroenterol; 2018 Nov; 24(44):4959-4961. PubMed ID: 30510370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Countdown to 2030: eliminating hepatitis B disease, China.
    Liu J; Liang W; Jing W; Liu M
    Bull World Health Organ; 2019 Mar; 97(3):230-238. PubMed ID: 30992636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How far is Mexico from Viral Hepatitis Global Health Sector Strategy 2030 targets.
    García-Sepúlveda CA; Laguna-Meraz S; Panduro A
    Ann Hepatol; 2020; 19(2):123-125. PubMed ID: 32138870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
    Lazarus JV; Stumo SR; Harris M; Hendrickx G; Hetherington KL; Maticic M; Jauffret-Roustide M; Tallada J; Simojoki K; Reic T; Safreed-Harmon K;
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25052. PubMed ID: 29633562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance for acute viral hepatitis--United States, 2006.
    Wasley A; Grytdal S; Gallagher K;
    MMWR Surveill Summ; 2008 Mar; 57(2):1-24. PubMed ID: 18354374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
    Ward JW; Hinman AR
    Gastroenterology; 2019 Jan; 156(2):297-310. PubMed ID: 30391470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research gaps in viral hepatitis.
    Boyd A; Duchesne L; Lacombe K
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25054. PubMed ID: 29633564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates.
    Kane A; Lloyd J; Zaffran M; Simonsen L; Kane M
    Bull World Health Organ; 1999; 77(10):801-7. PubMed ID: 10593027
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.